Picture EBD Group Bio-Europe Spring 2024 Barcelona 650x100px
Collaboration › Details

Bicycle Therapeutics–Leucadia: investor conference, 202311 supply service Bicycle Tx at Jefferies 2023 London Healthcare Conference


Period Period 2023-11-15
Region Region London, Greater London
  Country United Kingdom (GB)
Organisations Partner, 1st Bicycle Therapeutics plc (Nasdaq: BCYC)
  Group Bicycle Therapeutics (Group)
  Partner, 2nd Jefferies International Ltd.
  Group Leucadia (Group)
Products Product Jefferies 2024 London Healthcare Conference
  Product 2 Bicycles® platform (bicyclic peptides)
Person Person Sutton, Sarah (Argot Partners 202110 before WPP/Glover Park Group + Ten Bridge Communications)

Bicycle Therapeutics plc. (10/30/23). "Press Release: Bicycle Therapeutics to Participate in Upcoming Investor Conferences". Cambridge.

Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in the following investor conferences in November:

> TD Cowen 7th Annual Fall Oncology Innovation Summit on Friday, November 3, 2023; fireside chat at 10:00 a.m. ET

> Jefferies London Healthcare Conference on Wednesday, November 15, 2023; fireside chat at 11:00 a.m. ET

Live webcasts of the fireside chats will be accessible in the Investors section of Bicycle’s website at Archived replays of the webcasts will be available following the fireside chat dates.

About Bicycle Therapeutics

Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. The company is evaluating BT8009, a Bicycle Toxin Conjugate (BTC™) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2; and BT7480, a Bicycle TICA™ targeting Nectin-4 and agonizing CD137, in company-sponsored Phase 1/2 trials. In addition, BT1718, a BTC that targets MT1-MMP, is being investigated in an ongoing Phase 1/2a clinical trial sponsored by the Cancer Research UK Centre for Drug Development. Bicycle Therapeutics is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Cambridge, Mass. For more information, visit


Stephanie Yao
SVP, Investor Relations and Corporate Communications


Argot Partners
Sarah Sutton

Record changed: 2023-10-31


Picture Consultech GmbH Secure Funding with RnD Grants 650x200px

More documents for Bicycle Therapeutics (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture Berlin Partner Cardiovascular Health in Berlin-Brandenburg 650x300px

» top